Clinical trials: Liver Cell Carcinoma Non-resectable
Hepatocellular Carcinoma
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
Hepatocellular carcinoma (HCC) is a prevalent malignancy with great disease burden both in Taiwan and worldwide 1. Early stage HCC can be treated by surgical resection, radiofrequency ablation, embolization and liver…
- Trial name
- NCT05281926
- Testing
- Poly ICLC
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer).
- Trial name
- NCT00057382
- Testing
- T138067 intravenous, doxorubicin intravenous
- Where
- 76 sites in United States, Brazil and 9 more
- Volunteers
- 750 people
- Sponsor
- Tularik
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05103904
- Testing
- Laboratory Biomarker Analysis, Lenvatinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Hepatocellular Carcinoma, Donafenib
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
This study is a prospective, single-center, observational real-world study. It is planned to enroll 150 patients with unresectable hepatocellular carcinoma treated with Donafenib combined with TACE-based treatment, so as to…
- Trial name
- NCT05205629
- Testing
- Donafenib combined with TACE
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Neoplasms, Unresectable Hepatocellular Carcinoma
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
The study will consist of two parts. In Part 1 the study will start enrolling 38 patients and then further 25 patients up to a total of 63 eligible patients.
- Trial name
- NCT00247676
- Testing
- Sunitinib (SU011248)
- Where
- 8 sites in France, South Korea and 1 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
- Trial name
- NCT05925413
- Testing
- Cadonilimab+TACE
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.
- Trial name
- NCT04541173
- Testing
- Y-90 TARE, Atezolizumab, Bevacizumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aiwu Ruth He, MD
Safety Issues, Effect of Drug
MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma
A randomized, open, multicenter clinical trial design was adopted, planned to be conducted in three stages, with 91 participants expected to be included in the study to evaluate the efficacy, tolerance, and safety of different…
- Conditions
- Safety Issues, Effect of Drug, Tolerance
- Trial name
- MB07133 (NCT06141096)
- Testing
- MB07133
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Liver Cancer
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00109954
- Testing
- cisplatin, brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pittsburgh
Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
- Trial name
- SERENADE-T (NCT03283956)
- Testing
- Patient records
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Therapy
Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months
- Trial name
- NCT01097083
- Testing
- Coriolus Versicolor
- Where
- 3 sites in Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Unresectable Hepatocellular Carcinoma
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases.
- Trial name
- NCT04947956
- Testing
- Camrelizumab
- Volunteers
- 1,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepato Cellular Carcinoma (HCC)
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S.
- Trial name
- NCT06608940
- Testing
- BC3402, Durvalumab, Tremelimumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma
TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with methylcantharidimide tablets in the treatment of patients with large and unresectable hepatocellular…
- Trial name
- NCT03996681
- Testing
- methylcantharidimide tablets
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Municipal Hospital
Child-Pugh Class A, Child-Pugh Class B
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
- Trial name
- NCT02507765
- Testing
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
To determine the efficacy and toxicity of TACE combined with SBRT
- Conditions
- Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
- Trial name
- NCT01020812
- Testing
- TACE, SBRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
HCC - Hepatocellular Carcinoma
Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC
The goal of this clinical trial is to learn whether adding branched-chain amino acids (BCAAs) to lenvatinib and pembrolizumab improves treatment outcomes in adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BLP-HCC (NCT07412054)
- Testing
- Lenvatinib, Pembrolizumab, Branched-Chain Amino Acids
- Volunteers
- 234 people
- Sponsor
- Fudan University
Unresectable Hepatocellular Carcinoma
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
This study is a single-arm, single-center, non-randomized, open-label study. A total of 37 patients with locally advanced or metastatic HCC who have not received systemic therapy, are not suitable for radical surgical resection…
- Trial name
- NCT06590844
- Testing
- Injectable coenzyme I
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC
- Trial name
- NCT03969576
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Air Force Military Medical University, China
Carcinoma, Hepatocellular
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular…
- Trial name
- NCT00082082
- Testing
- Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE)
- Where
- 5 sites in United States
- Sponsor
- SciClone Pharmaceuticals